Biosimilars Market

Biosimilars Market (Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Market Outlook 2031

  • The global biosimilars market was valued at US$ 20.4 Bn in 2021
  • It is anticipated to reach more than US$ 85 Bn by the end of 2031 and to advance at a CAGR of 15.5% from 2022 to 2031

Analysts’ Viewpoint on Market Scenario

Several pharmaceutical companies across the world are engaged in the development of biosimilars. The global biosimilars market has the potential to grow at a rapid pace. Large numbers of biological drugs are likely to go off patent. Therefore, lower healthcare costs and regulatory structure changes by governments are expected to drive the market during the forecast period. Usage of monoclonal antibodies in the treatment of COVID-19 has also renewed interest in the market. However, implementation of strict policies and market entry barriers for new players are likely to restrain the global market. Manufacturers are increasing their research capabilities to develop improved immunotherapy drugs. These drugs hold the potential to reduce the incidence of side effects in cancer patients. Rise in availability of insurance coverage for biosimilars is also creating a positive impact on the market.

biosimilars market

Overview of the Biosimilars Market

Biosimilar can be defined as a biologic medical product, which is considered very similar to an already-approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and the standards of pharmaceutical quality that apply to all biologic medicines.

Biosimilars are generic versions of biologics that have passed their patent expiration date. The biosimilar market is expected to be driven by the patent expiration of well-known biologics. An increase in approval and sales of biosimilars has led to a significant decline in the sales of biologics that had a steady or growing demand.

The burden of chronic diseases has been rising across the globe. An increase in the prevalence of chronic diseases can be largely ascribed to the aging population and changing lifestyle of the people. Diabetes, hypertension, stroke, respiratory diseases, oral diseases, obesity, arthritis, and cancer are some of the common chronic diseases. On the other hand, biosimilar monoclonal antibodies are being extensively used in the treatment of rheumatoid arthritis and cancer.

Approvals of biosimilars have been increasing globally owing to changing regulations and the rise in pressure on healthcare systems to facilitate treatment for all patients. Biosimilars or copy biologics are being increasingly adopted by physicians, authorities, and patients, owing to the much-needed improvements in access to therapeutically viable options for the treatment of various diseases. Companies are increasing the production of biosimilar medicines, oncology biosimilars, and Remicade biosimilars to broaden their revenue streams.

Request a sample to get extensive insights into the Biosimilars Market

High Prevalence of Chronic Diseases and Rise in Number of Cancer Patients to Boost Market

The rise in the prevalence of chronic diseases is augmenting the global market. Biosimilar drugs are becoming increasingly popular across the world because of their cost-effectiveness. An increase in cancer patients and chronic disease cases; and growth in the geriatric population are projected to fuel the demand for biosimilars during the forecast period.

Over half of the population of the U.S. is likely to suffer from at least one chronic disease during their lifetime. According to the WHO, chronic disease prevalence is expected to rise by 57% by 2020. Rapid population growth in emerging markets is expected to drive the prevalence of chronic diseases.

Cancer is the second leading cause of death globally, with over 70% of deaths occurring in low- and middle-income countries. The incidence of cancer increases with age, most likely due to the rise in the risk of specific cancers as people get older. Growth in the pipeline of biosimilar drugs for the treatment of chronic diseases is projected to propel the global market in the next few years. ABRILADA, a biosimilar to Humira, was approved by the U.S. Food and Drug Administration (FDA) in November 2019 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

Changing Government Regulations to Augment Demand for Recombinant Non-glycosylated Protein Products

In terms of product, the recombinant non-glycosylated proteins segment held a relatively large market share in 2021. The segment has been split into insulin, granulocyte colony-stimulating factor, recombinant human growth factor, and interferons.

Recombinant non-glycosylation involves the production of active substances in bacteria, which results in non-glycosylation, allowing the active substance to remain biologically active. The growth of the segment can be attributed to the rise in the prevalence of chronic diseases, which require recombinant non-glycosylated proteins biosimilars for treatment. Additionally, changing regulations and an increase in the focus of governments on the approval of biosimilars are anticipated to drive the recombinant non-glycosylated proteins segment during the forecast period.

Advancements in Biomedical Technology to Drive Oncology Treatments

Based on indication, the oncology segment held a large revenue share of the global biosimilars market in 2021. Growth in the prevalence of cancer and an increase in the number of ongoing studies in the biosimilar field across the world are likely to augment the segment during the forecast period.

Biologics are a broad category of products that include blood and blood components, vaccines, hormones, and allergens (anti-allergy medications). Monoclonal antibodies are important biologics; these are used to treat a range of diseases, including breast cancer, lymphoma, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease.

Advancements in biomedical technology have resulted in an increase in the commercialization of biologics in the last few decades. This has improved cancer care. Cancer treatment is expensive; therefore, the development of a biosimilar product with comparable clinical efficacy has led to lower healthcare costs and improved access to care. Hence, the oncology segment is expected to account for a significant share of the market during the forecast period.

Regional Outlook of the Global Biosimilars Industry

Europe held more than 45% share of the global biosimilars market in 2021. It is projected to be a highly lucrative region of the global market, with a high market attractiveness index, during the forecast period.

The biosimilars market in Europe is the largest in the world, accounting for roughly 60% of the global market and growing steadily year after year. As of October 2019, 54 biosimilars of 15 originator biological medicines were approved for marketing in Europe. Countries in Europe provide valuable examples of different approaches to biosimilar policy, led by their large market and diverse healthcare systems.

Biosimilars sales reflect Europe's legislative and regulatory leadership in the market. The biosimilar market in the region is more mature than that in the U.S. However, opportunities for biosimilar companies in Europe are limited due to lower overall spending on biologicals.

Europe has set the standard, approving more treatments than any other continent. Currently, biosimilars account for 10% of the total biologics market in the region, with a majority (7%) occurring in the past five years. The percentage is significantly higher in terms of volume, reflecting the steadily increasing level of revenue savings as a result of the rise in biosimilar competition and penetration. More than 60 biosimilars have been approved for use in the European Union (EU) to date, with several more being evaluated. Therefore, the biosimilars market in Europe is expected to grow at a significant pace during the forecast period.

Analysis of Key Players

The biosimilars industry is consolidated, with a small number of leading players accounting for a relatively large share. Most companies are making significant investments in research & development activities. Diversification of product portfolios and mergers & acquisitions are important strategies adopted by key players in the global market for biosimilars. Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion, Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex, Inc. are the prominent players operating in the global market.

Request a custom report on Biosimilars Market

Key Developments in Global Biosimilars Market

  • In March 2022, Amneal Pharmaceuticals, Inc. announced that the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen, had been approved by the U.S. Food and Drug Administration (FDA). The product will be sold under the brand name RELEUKO.
  • In December 2021, Gedeon Richter, Hungary's largest drug maker, reached an agreement with Hikma Pharmaceuticals, a London-listed drug maker, to out-license biosimilars denosumab for commercialization in the U.S.
  • In July 2021, Biocon Ltd. (Biocon Biologics) received FDA approval for the first interchangeable biosimilar SEMGLEE (insulin glargine-yfgn injection) for the treatment of diabetes in collaboration with Viatris, Inc.

Each of these players has been profiled in the biosimilars market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Biosimilars Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 20.4 Bn

Market Forecast Value in 2031

More than US$ 85 Bn

Growth Rate

(CAGR)

15.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value & Tons for Volume

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Recombinant Glycosylated Proteins
      • Monoclonal Antibodies
      • Erythropoietin
      • Others
    • Recombinant Non-glycosylated Proteins
      • Insulin
      • Granulocyte Colony Stimulating Factor
      • Recombinant Human Growth Factor
      • Interferons
    • Recombinant Peptides
  • Indication
    • Chronic Diseases
    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases
    • Blood Disorders
    • Growth Hormone Deficiency
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Pfizer, Inc.
  • Intas Pharmaceuticals Ltd.
  • Biocon
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (A Novartis Division)
  • Celltrion Inc.
  • Amgen, Inc.
  • STADA Arzneimittel AG
  • Apotex Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global biosimilars market in 2021?

The global market was valued at US$ 20.4 Bn in 2021

How big will be the global market in 2031?

The global market is projected to reach more than US$ 85 Bn by 2031

What will be the CAGR of the global market during the forecast period (2022–2031)?

The global biosimilars market is anticipated to expand at a CAGR of 15.5% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in approvals of biosimilars is expected to drive the global market.

Which region will account for major share of the global market during the forecast period?

Europe is expected to account for major share of the global biosimilars market during the forecast period.

Who are the prominent players in the global market?

Prominent players in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion, Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Acronyms

    3. Research Methodology

    4. Executive Summary: Global Biosimilars Market

    5. Market Overview

        5.1. Definition

        5.2. Market Indicators

        5.3. Market Dynamics

            5.3.1. Drivers

            5.3.2. Restraints

            5.3.3. Opportunities

    6. Market Outlook

        6.1. Global Biosimilars Market Analysis and Forecast, 2017–2031

        6.2. Global Biosimilars Market Outlook

        6.3. Entry Barriers to Biosimilars Market

        6.4. Factors Driving the Adoption of Biosimilars

        6.5. Pipeline Analysis

        6.6. Regulatory Scenario Assessment

        6.7. Key Industry Developments

    7. Global Biosimilars Market Analysis and Forecast, by Product

        7.1. Introduction

        7.2. Biosimilars Market Value Forecast, by Product, 2017–2031

            7.2.1. Recombinant Glycosylated Proteins

                7.2.1.1. Monoclonal Antibodies

                7.2.1.2. Erythropoietin

                7.2.1.3. Others

            7.2.2. Recombinant Non-glycosylated Proteins

                7.2.2.1. Insulin

                7.2.2.2. Granulocyte Colony Stimulating Factor

                7.2.2.3. Recombinant Human Growth Factor

                7.2.2.4. Interferons

            7.2.3. Recombinant Peptides

        7.3. Market Attractiveness Analysis, by Product

    8. Global Biosimilars Market Analysis and Forecast, by Indication

        8.1. Introduction

        8.2. Biosimilars Market Value Forecast, by Indication, 2017–2031

            8.2.1. Chronic Diseases

            8.2.2. Oncology

            8.2.3. Autoimmune Diseases

            8.2.4. Infectious Diseases

            8.2.5. Blood Disorders

            8.2.6. Growth Hormone Deficiency

            8.2.7. Others

        8.3. Market Attractiveness Analysis, by Material

    9. Global Biosimilars Market Analysis and Forecast, by Region

        9.1. Regional Outlook

        9.2. Global Scenario

        9.3. Introduction

        9.4. Biosimilars Market Value Forecast, by Region

            9.4.1. North America

            9.4.2. Europe

            9.4.3. Asia Pacific

            9.4.4. Latin America

            9.4.5. Middle East & Africa

        9.5. Market Attractiveness Analysis, by Region

    10. North America Biosimilars Market Analysis and Forecast

        10.1. Key Findings

        10.2. North America Biosimilars Market Value Forecast, by Product, 2017–2031

            10.2.1. Recombinant Glycosylated Proteins

                10.2.1.1. Monoclonal Antibodies

                10.2.1.2. Erythropoietin

                10.2.1.3. Others

            10.2.2. Recombinant Non-glycosylated Proteins

                10.2.2.1. Insulin

                10.2.2.2. Granulocyte Colony Stimulating Factor

                10.2.2.3. Recombinant Human Growth Factor

                10.2.2.4. Interferons

            10.2.3. Recombinant Peptides

        10.3. North America Biosimilars Market Value Forecast, by Indication, 2017–2031

            10.3.1. Chronic Diseases

            10.3.2. Oncology

            10.3.3. Autoimmune Diseases

            10.3.4. Infectious Diseases

            10.3.5. Blood Disorders

            10.3.6. Growth Hormone Deficiency

            10.3.7. Others

        10.4. North America Biosimilars Market Value Forecast, by Country, 2017–2031

            10.4.1. U.S.

            10.4.2. Canada

        10.5. North America Biosimilars Market Attractiveness Analysis

            10.5.1. By Product

            10.5.2. By Indication

            10.5.3. By Country

    11. Europe Biosimilars Market Analysis and Forecast

        11.1. Key Findings

        11.2. Europe Biosimilars Market Value Forecast, by Product, 2017–2031

            11.2.1. Recombinant Glycosylated Proteins

                11.2.1.1. Monoclonal Antibodies

                11.2.1.2. Erythropoietin

                11.2.1.3. Others

            11.2.2. Recombinant Non-glycosylated Proteins

                11.2.2.1. Insulin

                11.2.2.2. Granulocyte Colony Stimulating Factor

                11.2.2.3. Recombinant Human Growth Factor

                11.2.2.4. Interferons

            11.2.3. Recombinant Peptides

        11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017–2031

            11.3.1. Chronic Diseases

            11.3.2. Oncology

            11.3.3. Autoimmune Diseases

            11.3.4. Infectious Diseases

            11.3.5. Blood Disorders

            11.3.6. Growth Hormone Deficiency

            11.3.7. Others

        11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. U.K.

            11.4.2. Germany

            11.4.3. France

            11.4.4. Italy

            11.4.5. Spain

            11.4.6. Rest of Europe

        11.5. Europe Biosimilars Market Attractiveness Analysis

            11.5.1. By Product

            11.5.2. By Indication

            11.5.3. By Country/Sub-region

    12. Asia Pacific Biosimilars Market Analysis and Forecast

        12.1. Key Findings

        12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017–2031

            12.2.1. Recombinant Glycosylated Proteins

                12.2.1.1. Monoclonal Antibodies

                12.2.1.2. Erythropoietin

                12.2.1.3. Others

            12.2.2. Recombinant Non-glycosylated Proteins

                12.2.2.1. Insulin

                12.2.2.2. Granulocyte Colony Stimulating Factor

                12.2.2.3. Recombinant Human Growth Factor

                12.2.2.4. Interferons

            12.2.3. Recombinant Peptides

        12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017–2031

            12.3.1. Chronic Diseases

            12.3.2. Oncology

            12.3.3. Autoimmune Diseases

            12.3.4. Infectious Diseases

            12.3.5. Blood Disorders

            12.3.6. Growth Hormone Deficiency

            12.3.7. Others

        12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. China

            12.4.2. India

            12.4.3. Japan

            12.4.4. Australia & New Zealand

            12.4.5. Rest of Asia Pacific

        12.5. Asia Pacific Biosimilars Market Attractiveness Analysis

            12.5.1. By Product

            12.5.2. By Indication

            12.5.3. By Country/Sub-region

    13. Latin America Biosimilars Market Analysis and Forecast

        13.1. Key Findings

        13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017–2031

            13.2.1. Recombinant Glycosylated Proteins

                13.2.1.1. Monoclonal Antibodies

                13.2.1.2. Erythropoietin

                13.2.1.3. Others

            13.2.2. Recombinant Non-glycosylated Proteins

                13.2.2.1. Insulin

                13.2.2.2. Granulocyte Colony Stimulating Factor

                13.2.2.3. Recombinant Human Growth Factor

                13.2.2.4. Interferons

            13.2.3. Recombinant Peptides

        13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017–2031

            13.3.1. Chronic Diseases

            13.3.2. Oncology

            13.3.3. Autoimmune Diseases

            13.3.4. Infectious Diseases

            13.3.5. Blood Disorders

            13.3.6. Growth Hormone Deficiency

            13.3.7. Others

        13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. Brazil

            13.4.2. Mexico

            13.4.3. Rest of Latin America

        13.5. Latin America Biosimilars Market Attractiveness Analysis

            13.5.1. By Product

            13.5.2. By Indication

            13.5.3. By Country/Sub-region

    14. Middle East & Africa Biosimilars Market Analysis and Forecast

        14.1. Key Findings

        14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017–2031

            14.2.1. Recombinant Glycosylated Proteins

                14.2.1.1. Monoclonal Antibodies

                14.2.1.2. Erythropoietin

                14.2.1.3. Others

            14.2.2. Recombinant Non-glycosylated Proteins

                14.2.2.1. Insulin

                14.2.2.2. Granulocyte Colony Stimulating Factor

                14.2.2.3. Recombinant Human Growth Factor

                14.2.2.4. Interferons

            14.2.3. Recombinant Peptides

        14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017–2031

            14.3.1. Chronic Diseases

            14.3.2. Oncology

            14.3.3. Autoimmune Diseases

            14.3.4. Infectious Diseases

            14.3.5. Blood Disorders

            14.3.6. Growth Hormone Deficiency

            14.3.7. Others

        14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031

            14.4.1. GCC Countries

            14.4.2. South Africa

            14.4.3. Rest of Middle East & Africa

        14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis

            14.5.1. By Product

            14.5.2. By Indication

            14.5.3. By Country/Sub-region

    15. Competition Landscape

        15.1. Competition Matrix

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Pfizer, Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Financial Overview

                15.3.1.3. Product Portfolio

                15.3.1.4. Strategic Overview

                15.3.1.5. SWOT Analysis

            15.3.2. Intas Pharmaceuticals Ltd.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Financial Overview

                15.3.2.3. Product Portfolio

                15.3.2.4. Strategic Overview

                15.3.2.5. SWOT Analysis

            15.3.3. Biocon

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Financial Overview

                15.3.3.3. Product Portfolio

                15.3.3.4. Strategic Overview

                15.3.3.5. SWOT Analysis

            15.3.4. Dr. Reddy’s Laboratories Ltd.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Financial Overview

                15.3.4.3. Product Portfolio

                15.3.4.4. Strategic Overview

                15.3.4.5. SWOT Analysis

            15.3.5. Teva Pharmaceutical Industries Ltd.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Financial Overview

                15.3.5.3. Product Portfolio

                15.3.5.4. Strategic Overview

                15.3.5.5. SWOT Analysis

            15.3.6. Sandoz International GmbH (A Novartis Division)

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Financial Overview

                15.3.6.3. Product Portfolio

                15.3.6.4. Strategic Overview

                15.3.6.5. SWOT Analysis

            15.3.7. Celltrion, Inc.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Financial Overview

                15.3.7.3. Product Portfolio

                15.3.7.4. Strategic Overview

                15.3.7.5. SWOT Analysis

            15.3.8. Amgen, Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Financial Overview

                15.3.8.3. Product Portfolio

                15.3.8.4. Strategic Overview

                15.3.8.5. SWOT Analysis

            15.3.9. STADA Arzneimittel AG

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Financial Overview

                15.3.9.3. Product Portfolio

                15.3.9.4. Strategic Overview

                15.3.9.5. SWOT Analysis

            15.3.10. Apotex Inc. (Apobiologix)

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Financial Overview

                15.3.10.3. Product Portfolio

                15.3.10.4. Strategic Overview

                15.3.10.5. SWOT Analysis

    List of Tables

    Table 01: Pipeline Analysis - Biosimilars

    Table 02: Global Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 03: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Table 04: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Table 05: Global Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

    Table 06: Global Biosimilars Market Value (US$ Bn) Forecast, by Region, 2017–2031

    Table 07: North America Biosimilars Market Value (US$ Bn) Forecast, by Country, 2017–2031

    Table 08: North America Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031

    Table 09: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Table 10: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Table 11: North America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

    Table 12: Europe Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Europe Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031

    Table 14: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Table 15: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Table 16: Europe Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

    Table 17: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 19: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Table 20: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Table 21: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

    Table 22: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 23: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 24: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Table 25: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Table 26: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

    Table 27: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 28: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 29: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Table 30: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Table 31: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031

    List of Figures

    Figure 01: Global Biosimilars Market Snapshot

    Figure 02: Global Biosimilars Market Value (US$ Bn) by Region, 2021 and 2031

    Figure 03: Global Biosimilars Market Value (US$ Bn) Forecast, 2021–2031

    Figure 04: Global Biosimilars Market Value Share (%), by Product, 2021

    Figure 05: Global Biosimilars Market Value Share (%), by Indication, 2021

    Figure 06: Global Biosimilars Market Value Share (%), by Region, 2021

    Figure 07: Entry Barriers to Biosimilars Market

    Figure 08: Factors Driving the Adoption of Biosimilars

    Figure 09: Biosimilar Approval Process - US

    Figure 10: Data Requirements for Biosimilar Approval in Europe

    Figure 11: Regulations for Biosimilar Approval in Japan

    Figure 12: Regulations for Biosimilar Approval in India

    Figure 13: Regulations for Biosimilar Approval in Brazil

    Figure 14: Regulations for Biosimilar Approval in Saudi Arabia

    Figure 15: Biosimilars Market - Key Product Launches

    Figure 16: Global Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

    Figure 17: Global Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 18: Global Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 19: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031

    Figure 20: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031

    Figure 21: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Peptides, 2017–2031

    Figure 22: Global Biosimilars Market Value (US$ Bn) Forecast, by Monoclonal Antibodies, 2017–2031

    Figure 23: Global Biosimilars Market Value (US$ Bn) Forecast, by Erythropoietin, 2017–2031

    Figure 24: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017–2031

    Figure 25: Global Biosimilars Market Value (US$ Bn) Forecast, by Insulin, 2017–2031

    Figure 26: Global Biosimilars Market Value (US$ Bn) Forecast, by Granulocyte Colony Stimulating Factor, 2017–2031

    Figure 27: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Human Growth Factor, 2017–2031

    Figure 28: Global Biosimilars Market Value (US$ Bn) Forecast, by Interferons, 2017–2031

    Figure 29: Global Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

    Figure 30: Global Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 31: Global Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 32: Global Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 33: Global Biosimilars Market Value (US$ Bn) Forecast, by Chronic Diseases, 2017–2031

    Figure 34: Global Biosimilars Market Value (US$ Bn) Forecast, by Oncology, 2017–2031

    Figure 35: Global Biosimilars Market Value (US$ Bn) Forecast, by Autoimmune Diseases, 2017–2031

    Figure 36: Global Biosimilars Market Value (US$ Bn) Forecast, by Infectious Diseases, 2017–2031

    Figure 37: Global Biosimilars Market Value (US$ Bn) Forecast, by Blood Disorders, 2017–2031

    Figure 38: Global Biosimilars Market Value (US$ Bn) Forecast, by Growth Hormone Deficiency, 2017–2031

    Figure 39: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017–2031

    Figure 40: Global Biosimilars Market Attractiveness Analysis, by Indication, 2021-2031

    Figure 41: Global Biosimilars Market: Regional Outlook

    Figure 42: Global Biosimilars Market Value Share Analysis, by Region, 2021 and 2031

    Figure 43: Global Biosimilars Market Attractiveness Analysis, by Region, 2021-2031

    Figure 44: North America Biosimilars Market Value (US$ Bn) Forecast, 2017–2031

    Figure 45: North America Biosimilars Market Value Share Analysis, by Country, 2021 and 2031

    Figure 46: North America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

    Figure 47: North America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 48: North America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 49: North America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 50: North America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

    Figure 51: North America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 52: North America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 53: North America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

    Figure 54: North America Biosimilars Market Attractiveness Analysis, by Country, 2021 and 2031

    Figure 55: Europe Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

    Figure 56: Europe Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 57: Europe Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

    Figure 58: Europe Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 59: Europe Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 60: Europe Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 61: Europe Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

    Figure 62: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 63: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 64: Europe Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

    Figure 65: Europe Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

    Figure 66: Asia Pacific Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

    Figure 67: Asia Pacific Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 68: Asia Pacific Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

    Figure 69: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 70: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 71: Asia Pacific Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 72: Asia Pacific Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

    Figure 73: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 74: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 75: Asia Pacific Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

    Figure 76: Asia Pacific Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

    Figure 77: Latin America Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

    Figure 78: Latin America Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 79: Latin America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

    Figure 80: Latin America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 81: Latin America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 82: Latin America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 83: Latin America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

    Figure 84: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 85: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 86: Latin America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

    Figure 87: Latin America Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

    Figure 88: Middle East & Africa Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

    Figure 89: Middle East & Africa Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 90: Middle East & Africa Biosimilars Market Value Share Analysis, by Product, 2021 and 2031

    Figure 91: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 92: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 93: Middle East & Africa Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 94: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031

    Figure 95: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031

    Figure 96: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031

    Figure 97: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031

    Figure 98: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031

    Figure 99: Global Biosimilars Market Share Analysis, by Company, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved